Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,012.82 USD

1,012.82
1,071,783

-1.77 (-0.17%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron (REGN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $591.13 in the latest trading session, marking a -1.09% move from the prior day.

Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted

by Zacks Equity Research

FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Regeneron (REGN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $612.49 in the latest trading session, marking a +0.84% move from the prior day.

Regeneron (REGN) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed the most recent trading day at $586.84, moving -0.14% from the previous trading session.

Regeneron (REGN) Moves 4.4% Higher: Will This Strength Last?

by Zacks Equity Research

Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Regeneron (REGN) Stock Moves -0.79%: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $556.75 in the latest trading session, marking a -0.79% move from the prior day.

Regeneron (REGN) Stock Moves -0.64%: What You Should Know

by Zacks Equity Research

Regeneron (REGN) closed at $571.81 in the latest trading session, marking a -0.64% move from the prior day.

Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study

by Zacks Equity Research

Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to GSK's MMR Jab & SNY's Dupixent Expanded Use

by Kinjel Shah

European Commission approves Roche's (RHHBY) Tecentriq for a new indication. FDA gives the nod to Glaxo's (GSK) new MMR vaccine and Sanofi (SNY) and Regeneron's (REGN) Dupixent for expanded use.

The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics

by Zacks Equity Research

Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.

Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More

by Zacks Equity Research

Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.

Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year

by Zacks Equity Research

Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.

Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down

by Zacks Equity Research

Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.

Regeneron (REGN) Down 1.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB

by Zacks Equity Research

Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.

Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority Tag

by Zacks Equity Research

The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.

SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

by Zacks Equity Research

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates

by Zacks Equity Research

Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)

by Zacks Equity Research

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Regeneron's (REGN) Evkeeza Positive in Late-Stage Study

by Zacks Equity Research

Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication

by Zacks Equity Research

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical

by Zacks Equity Research

Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical are part of Zacks top Analyst Blog

Ekta Bagri headshot

Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News

by Ekta Bagri

Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.